Sido Muncul's Sales Reach IDR 4.02 Trillion Throughout 2021, Growing 20 Percent Compared To Achievements In 2020

Director of Sido Muncul, Irwan Hidayat. (Photo: Doc. Sido Appears)

JAKARTA - PT Sido Muncul Herbal and Pharmaceutical Industry Tbk posted performance growth throughout 2021. The issuer with stock code SIDO scored double-digit growth in terms of sales and net profit.

In SIDO's financial report published on the Indonesia Stock Exchange website, quoted on Monday 7 February, the producer of Tolak Angin and Kuku Bima Energy posted sales of up to IDR 4.02 trillion in 2021. This achievement increased by 20.55 percent year on year (yoy) compared to 2020 where SIDO posted sales of IDR 3.33 trillion.

Each compact SIDO sales segment recorded growth. The highest increase was recorded by the pharmaceutical sales segment which grew by 26.48 percent yoy.

Although the increase was the highest, the contribution to SIDO's sales was minimal, at IDR 137.14 billion throughout the year.

Meanwhile, sales of herbal herbs and supplements increased by 21.27 percent yoy to IDR 2.69 trillion from IDR 2.22 trillion. This achievement made herbal medicine and supplements the highest contributor to SIDO sales last year.

Sales of food and beverages also rose 18.34 percent yoy to Rp1.19 trillion from the previous Rp1 trillion. The increase from the top line also raised SIDO's bottom line to 35 percent yoy.

Throughout 2021, the profit for the year attributable to the parent entity was able to penetrate IDR 1 trillion, to be exact, IDR 1.26 trillion, whereas in 2020, SIDO's profit was recorded at IDR 934.01 billion.

For your information, SIDO's total assets as of the end of last year were recorded at IDR 4.06 trillion. This number rose 5.70 percent yoy from IDR 3.84 trillion.

Its total liabilities decreased 4.78 percent yoy to IDR 597.78 billion and its total equity increased 7.74 percent yoy to IDR 3.47 trillion.